News & Updates
Filter by Specialty:
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
20 Jul 2022
Cannabidiol shots safe but of no benefit in drug-resistant focal epilepsy
In the treatment of patients with drug-resistant focal epilepsy, transdermally administered cannabidiol is well tolerated but is not superior to placebo in terms of reducing seizure frequency, according to a study.
Cannabidiol shots safe but of no benefit in drug-resistant focal epilepsy
18 Jul 2022
Resmetirom demos potential in NASH
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.
Resmetirom demos potential in NASH
18 Jul 2022
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
In the final analysis of the phase III ICON8* study, a weekly dose-dense chemotherapy (CT) regimen comprising paclitaxel and carboplatin did not improve survival outcomes in women with epithelial ovarian cancer** compared with the standard first-line (1L) paclitaxel-carboplatin regimen given once every 3 weeks (Q3W).
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
18 Jul 2022
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.
